NCT02245217View on ClinicalTrials.gov

Multi-Tracer PET Prediction and Assessment of Response to Gemcitabine in Pancreatic Cancer Patients

NACompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 12, 2014

Primary Completion Date

March 17, 2016

Study Completion Date

March 17, 2016

Conditions
Pancreatic Cancer
Interventions
DEVICE

PET/CT scan to assess treatment efficacy

Trial Locations (1)

84112

Huntsman Cancer Institute, Salt Lake City

All Listed Sponsors
lead

University of Utah

OTHER

NCT02245217 - Multi-Tracer PET Prediction and Assessment of Response to Gemcitabine in Pancreatic Cancer Patients | Biotech Hunter | Biotech Hunter